| Overview |
| bs-11643R-FITC |
| CLACP/COL25A1 Polyclonal Antibody, FITC Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Mouse, Rat |
| Human, Dog, Cow, Sheep, Horse, Chicken |
| Specifications |
| FITC |
| Rabbit |
| KLH conjugated synthetic peptide derived from human CLACP/COL25A1 |
| 581-654/654 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| Secreted, Cell membrane |
| Alzheimer disease amyloid associated protein; AMY; CLAC; CLAC P; CLAC precursor; COL25A1; COL25A1 protein; Collagen alpha 1 XXV chain; Collagen alpha 1XXV chain; Collagen like Alzheimer amyloid plaque component; Collagen like Alzheimer amyloid plaque component precursor; Collagen type XXV alpha 1; Collagenous Alzheimer amyloid plaque component. |
| Collagen proteins (products of the COL gene family) are fibrous, extracellular matrix proteins with high tensile strength and are the major components of connective tissue such as tendons and cartilage. All collagens contain a triple helix domain and frequently show lateral self-association in order to form complex connective tissues. The Collagen Type XXV precursor produces the proteolytic fragment CLAC (collagenous Alzheimer amyloid plaque component), which deposits in senile plaques associated with amyloid beta peptides (Abeta) in the brains of patients with Alzheimer's disease. CLAC binds to the fibrillized form of Abeta, which disturbs the structure and function of plasma membranes. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz